Lytix Biopharma: NOK80m Raised - Redeye
Bildkälla: Stockfoto

Lytix Biopharma: NOK80m Raised - Redeye

Redeye views the NOK80m directed share issue as a sensible move. It removes the financing overhang ahead of the full NeoLIPA data at ESMO IO in December and strengthens Lytix's hand in partnering discussions. The raise is close to what we had already assumed in our model, and our Fair Value is unchanged at NOK15.

Redeye views the NOK80m directed share issue as a sensible move. It removes the financing overhang ahead of the full NeoLIPA data at ESMO IO in December and strengthens Lytix's hand in partnering discussions. The raise is close to what we had already assumed in our model, and our Fair Value is unchanged at NOK15.
Börsvärldens nyhetsbrev